Eli Lilly and Com…
USUSDEli Lilly and Company (US:LLY) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 6. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte kohta
- Veebileht
- lilly.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- Indianapolis, United States
- Tegevjuht
- David A. Ricks
- Töötajad
- 38 350
- Asutatud
- 1875
- Ringluses olevad aktsiad
- Vabalt kaubeldavad aktsiad
- 888.95 mln
- Turukapitalisatsioon
- 1.03 trl USD
- Siseringi isikud
- 0.16%
- Institutsionaalsed investorid
- 85.32%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- Õiguslik vorm
- R0BI
- ISIN
- US5324571083
- LEI
- FRDRIPF3EKNDJ2CQJL29
- Väljamaksesuhe
- 21.7%
- FCF
- 13.6 mld USD43%
- Võlg
- 54.9 mld USD3.4 a FCF
- Dividendistaaž
- 53 a
Kirjeldus
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Börsid ja tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | LLY | USD | 1 143.12 +0.02% | tavalised aktsiad |
| MI Borsa Italiana (Milan) | 1LLY | EUR | 1 026 -0.10% | tavalised aktsiad |
| MX Mexican Stock Exchange | LLY | MXN | — | tavalised aktsiad |
| SW SIX Swiss Exchange | LLY | CHF | 980 +0.00% | tavalised aktsiad |
| VI Vienna Stock Exchange | LLYC | EUR | 1 023.2 | tavalised aktsiad |
| XETRA Xetra | LLY | EUR | 1 023.2 -2.29% | tavalised aktsiad |
Dividendid
| Ex-kuupäev | Väljamakse | Summa | % | Tüüp | Tikker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 1.7300 USD | 0.2/≈0.6 % | kord kvartalis | US:LLY |
| 2026-05-15 | 2026-06-10 | 1.7300 USD | 0.2/≈0.6 % | kord kvartalis | US:LLY |
| 2026-02-13 | 2026-03-10 | 1.7300 USD | 0.2/≈0.6 % | kord kvartalis | US:LLY |
News this week
Ettevõtte veebisaidilt uudiseid veel pole.
Suurimad omanikud
| Omanik | Osalus | Aktsiad | Aruande kuupäev |
|---|---|---|---|
| Lilly Endowment, Inc (Be… | 9.6% | 91.88 mln | 2026-06-30 |
| Blackrock Inc. | 7.17% | 67.54 mln | 2026-06-30 |
| Vanguard Capital Managem… | 5.69% | 53.53 mln | 2026-06-30 |
| PNC Financial Services G… | 5.45% | 51.32 mln | 2026-06-30 |
| State Street Corporation | 3.85% | 36.22 mln | 2026-06-30 |
| FMR, LLC | 3.02% | 28.46 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.86% | 26.91 mln | 2026-06-30 |
| Capital Research Global… | 2.22% | 20.87 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.22% | 20.86 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 20.5 mln | 2026-06-30 |
| Geode Capital Management… | 2.16% | 20.31 mln | 2026-06-30 |
| Morgan Stanley | 1.72% | 16.23 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.12% | 10.53 mln | 2026-08-31 |
| Fidelity Concord Street… | 1.09% | 10.23 mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.03% | 9.68 mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.94% | 8.87 mln | 2026-06-30 |
| Growth Fund of America | 0.89% | 8.36 mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.6% | 5.69 mln | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.58% | 5.41 mln | 2026-06-30 |
| Investment Co of America | 0.48% | 4.52 mln | 2026-06-30 |
| RICKS DAVID A (Chief Exe… | ≈0.08% | 708 781 | 2026-02-09 |
| SKOVRONSKY DANIEL (Offic… | ≈0.03% | 235 688 | 2026-02-09 |
| FYRWALD J. ERIK (Directo… | ≈0.01% | 75 536 | 2026-09-21 |
| WHITE ANNE E (President) | ≈0.01% | 74 209 | 2025-02-10 |
| ALVAREZ RALPH (Director) | ≈0.01% | 56 596 | 2026-09-21 |
| JONSSON PATRIK (Officer) | ≈0.01% | 54 779 | 2026-08-17 |
| HERNANDEZ EDGARDO (Offic… | ≈0% | 46 956 | 2026-09-02 |
| VAN NAARDEN JACOB S. (Of… | ≈0% | 36 270 | 2026-02-09 |
| HAKIM ANAT (General Coun… | — | — | 2026-08-07 |
Järelevalveasutuse sündmused
| Kuupäev | Järelevalveasutus | Sündmus | Üksikasjad |
|---|---|---|---|
| 2026-10-02 | ESMA | оновлення даних інструмента | ISIN, майданчик HAND |